Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Amgen Presents Late-Breaking Phase 2 Olpasiran Data at ESC 2023
Amgen Presents Late-Breaking Phase 2 Olpasiran Data at ESC 2023
Amgen Presents Late-Breaking Phase 2 Olpasiran Data at ESC 2023
Submitted by
admin
on August 28, 2023 - 12:02pm
Source:
BioSpace
News Tags:
Amgen
cardiovascular disease
olpasiran
clinical trials
Headline:
Amgen Presents Late-Breaking Phase 2 Olpasiran Data at ESC 2023
snippet:
Amgen is Changing the Cardiovascular Disease Treatment Landscape With New Research on Innovative Lipid Management
New Olpasiran Phase 2 Data Demonstrates Continued Reduction of Lp(a) Nearly a Year After the Last Dose
Do Not Allow Advertisers to Use My Personal information
